Shanghai Junshi Biosciences (SEHK:1877) Stock Faces Q3 Earnings Loss Despite Revenue Growth

Simply Wall St.

10/30

Shanghai Junshi Biosciences shares closed at HK$15.26 on Friday, capping a rough month where the stock slid about 21%. The Q3 2026 print then landed with a thud on earnings, showing a net loss of ¥...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2679765218"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2679765218\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2679765218?lang=zh_CN&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","is_english":true,"pubTime":"2026-10-30 18:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2679765218","market":"sg","top_or_hot":-1,"title":"Shanghai Junshi Biosciences (SEHK:1877) Stock Faces Q3 Earnings Loss Despite Revenue Growth","media":"Simply Wall St.","content":"<div>\n<p>Shanghai Junshi Biosciences shares closed at HK$15.26 on Friday, capping a rough month where the stock slid about 21%. The Q3 2026 print then landed with a thud on earnings, showing a net loss of ¥...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1877/shanghai-junshi-biosciences-shares/news/shanghai-junshi-biosciences-sehk1877-stock-faces-q3-earnings\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Junshi Biosciences (SEHK:1877) Stock Faces Q3 Earnings Loss Despite Revenue Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Junshi Biosciences (SEHK:1877) Stock Faces Q3 Earnings Loss Despite Revenue Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-30 18:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1877/shanghai-junshi-biosciences-shares/news/shanghai-junshi-biosciences-sehk1877-stock-faces-q3-earnings><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shanghai Junshi Biosciences shares closed at HK$15.26 on Friday, capping a rough month where the stock slid about 21%. The Q3 2026 print then landed with a thud on earnings, showing a net loss of ¥...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1877/shanghai-junshi-biosciences-shares/news/shanghai-junshi-biosciences-sehk1877-stock-faces-q3-earnings\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VOTE","symbol_name":"TCW Transform 500 ETF","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1877/shanghai-junshi-biosciences-shares/news/shanghai-junshi-biosciences-sehk1877-stock-faces-q3-earnings","article_id":"2679765218","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1877/shanghai-junshi-biosciences-shares/news/shanghai-junshi-biosciences-sehk1877-stock-faces-q3-earnings","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2679765218","pubTimestamp":1793356052,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Shanghai Junshi Biosciences shares closed at HK$15.26 on Friday, capping a rough month where the stock slid about 21%. The Q3 2026 print then landed with a thud on earnings, showing a net loss of ¥170.9 million and basic earnings per share back in the red at ¥0.21 loss per share.\nShort term traders see another biotech setback. Longer term investors will focus on the bigger question that now hangs over Junshi: whether a loss making quarter interrupts the path implied by forecasts that point to...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"VOTE":"TCW Transform 500 ETF","GXDW":"Global X Dorsey Wright Thematic ETF","PMDE":"PGIM S&P 500 Max Buffer ETF - December","VGFPF":"Vanguard Funds PLC","JOYT":"JPMorgan Equity and Options Total Return ETF","BK1583":"高瓴概念","FEBU":"AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF","BK1515":"抗疫概念","BK1161":"生物科技","01877":"君实生物","DECU":"AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF","RGLO":"Global Equity Active ETF"},"translate_title":"尽管收入增长，上海君实生物科技（SEHK:1877）股票仍面临第三季度盈利亏损","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DECU":0.61,"JOYT":0.61,"VGFPF":0.61,"VOTE":0.61,"PMDE":0.61,"01877":0.9,"RGLO":0.61,"FEBU":0.61,"GXDW":0.61},"content_text":"Shanghai Junshi Biosciences shares closed at HK$15.26 on Friday, capping a rough month where the stock slid about 21%. The Q3 2026 print then landed with a thud on earnings, showing a net loss of ¥170.9 million and basic earnings per share back in the red at ¥0.21 loss per share. Short term traders see another biotech setback. Longer term investors will focus on the bigger question that now hangs over Junshi: whether a loss making quarter interrupts the path implied by forecasts that point to earnings improvement and potential profitability over the next few years. Love the long term earnings potential at Shanghai Junshi Biosciences but concerned about another loss making quarter and share price pressure this month? Check out the list of solid balance sheet and fundamentals stocks (203 results). AdvertisementQ3 2026 Earnings Summary  Revenue (Q3 2026 vs Q3 2025): ¥817.2 million vs. ¥637.5 million (top line increase of about 28%) Net Loss (Q3 2026 vs Q3 2025): ¥170.9 million loss vs. ¥183.0 million loss (slightly narrower quarterly loss) Basic EPS (Q3 2026 vs Q3 2025): ¥0.21 loss per share vs. ¥0.18 loss per share (per share loss widened) Trailing 12 Month Revenue (Q3 2026 vs Q3 2025): ¥3.21b vs. ¥2.33b (higher revenue base over the last year)  Prefer clean charts over another wall of earnings tables and footnotes? See Shanghai Junshi Biosciences' full visual financial picture, including a clear view of its path from recurring losses toward potential profitability, in the company report for Shanghai Junshi Biosciences. SEHK:1877 Trailing 12-Month Revenue & Expenses Breakdown as at Oct 2026 Shanghai Junshi Biosciences: What Still Appeals To Bulls Shanghai Junshi Biosciences gives growth optimists something to work with. Revenue of ¥817.2 million in Q3 2026, alongside trailing 12 month sales of ¥3.21b, points to a larger commercial base than a year ago. Recent NMPA label expansion for toripalimab in resectable NSCLC and acceptance of the subcutaneous toripalimab sNDA support the idea of a broadening oncology franchise. New phase 3 starts for JS203 and JS207 plus JS007 keep the multi asset story alive, which aligns with investors who focus on pipeline breadth and ongoing product launches. Shanghai Junshi Biosciences: Where The Bear Story Bites The bear case leans on profitability and execution risk, and the latest quarter does not really soften that view. Shanghai Junshi Biosciences posted a net loss of ¥170.9 million and a wider ¥0.21 loss per share despite higher sales. That tension between revenue and earnings keeps questions around spending discipline front and center. A share price that has fallen about 21% over 30 days suggests traders remain cautious. A crowded trial calendar and expanding toripalimab label both require sustained funding, which keeps concerns about ongoing cash usage and pipeline risk very much alive. Losses, a packed trial schedule and a share price under pressure all raise the same question for Shanghai Junshi Biosciences: Can the balance sheet really fund this plan without painful dilution or liquidity stress? Verify the runway, cash position and debt profile in the financial health analysis of Shanghai Junshi Biosciences stock Hunt Quiet Disconnects In Earnings Shanghai Junshi Biosciences reminds investors that revenue gains can appear together with quarterly losses. The real opportunity sits in finding stocks that could be undervalued before the market closes the gap.  Company 1 - 24% below our estimate - uses cable project backlogs and high capacity utilization to secure long dated grid and energy transition contracts. Company 2 - 25% below our estimate - advances copper projects that move from delayed pre-stripping toward higher output as permits and development work progress. Company 3 - 33% below our estimate - shifts toward seeds, sustainable inputs and digital farming tools as growers adopt integrated platforms.  Three companies from the same screener. Open every one of the 197 undervalued companies on it → This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}